Skip to main content
Clinical Trials/NCT03058666
NCT03058666CompletedPhase 3

Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

ONY22 sites in 1 country477 target enrollmentStarted: March 29, 2017Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
477
Locations
22
Primary Endpoint
Intubation and Instillation of Liquid Surfactant

Study Overview

Brief Summary

Study to test the hypothesis that aerosolized Infasurf can decrease the need for intubation and instillation of liquid surfactant to the airway.

Detailed Description

Treatment will not be masked. The study objective is to document that aerosolized Infasurf is superior to "usual care" and provides for some patients effective surfactant therapy with less need for endotracheal intubation and instillation of a surfactant suspension into the airway. Two cohorts will be recruited: (a) patients who did not receive surfactant at birth who develop RDS in the first hours of life and (b) patients who received instillation of surfactant for RDS in the first hour of life, were extubated, and have continuing RDS.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
1 Hour to 24 Hours (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • RDS Patients
  • NICU patient, ≥1hour of age and <24 hours of age.
  • Clinical diagnosis of RDS, with or without chest X-ray data.
  • Inspired oxygen ≥21% to maintain adequate oxygen saturation.
  • Not intubated
  • nasal continuous positive airway pressure (nCPAP).

Exclusion Criteria

  • Congenital anomaly limiting care options or requiring early surgery.
  • Cardiopulmonary decompensation.
  • hypotension with metabolic acidosis (base excess < -10 meq/l).
  • Oxygen saturations < 88% at start of aerosolization.
  • PaCO2 ≥ 60 mmHg at start of aerosolization.
  • Grade 3 or Grade 4 intraventricular hemorrhage by cranial ultrasound, if known.
  • Acute hypoxic encephalopathy with or without seizures.

Arms & Interventions

Aerosolized Calfactant

Experimental
  1. NICU Patients with a clinical diagnosis of RDS
  2. Inspired oxygen ≥21% to maintain adequate oxygen saturation
  3. Not Intubated
  4. Requiring Nasal continuous positive airway pressure

Intervention: Aerosolized Calfactant (Drug)

Aerosolized Calfactant

Experimental
  1. NICU Patients with a clinical diagnosis of RDS
  2. Inspired oxygen ≥21% to maintain adequate oxygen saturation
  3. Not Intubated
  4. Requiring Nasal continuous positive airway pressure

Intervention: Solarys (Device)

Outcomes

Primary Outcomes

Intubation and Instillation of Liquid Surfactant

Time Frame: 72 hours

Percent of at risk subjects receiving endotracheal intubation and instillation of surfactant within the first 72 hours.

Secondary Outcomes

  • Respiratory Support Requirements(28 days)
  • Air Leak(28 days)

Investigators

Sponsor
ONY
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (22)

Loading locations...

Similar Trials